TABLE 1

Summary of demographic and baseline characteristicsa

ParameterNo. (%) of patients
FINA05FINA10CIPRO10Total
Patients76 (100.0)75 (100.0)72 (100.0)223 (100.0)
Caucasian race76 (100.0)75 (100.0)72 (100.0)223 (100.0)
Gender
    Male12 (15.8)13 (17.3)15 (20.8)40 (17.9)
    Female64 (84.2)62 (82.7)57 (79.2)183 (82.1)
Age group (yr)
    ≤3517 (22.4)14 (18.7)23 (31.9)54 (24.2)
    36–≤6536 (47.4)30 (40.0)27 (37.5)93 (41.7)
    ≥6623 (30.3)31 (41.3)22 (30.6)76 (34.1)
Diagnosis
    cUTI24 (31.6)22 (29.3)21 (29.2)67 (30.0)
    uPN47 (61.8)45 (60.0)46 (63.9)138 (61.9)
    cPN5 (6.6)8 (10.7)5 (6.9)18 (8.1)
mITT population64 (84.2)68 (90.7)61 (84.7)193 (86.6)
  • a Race, gender, age group, and diagnosis are given for the safety population for patients receiving 800 mg finafloxacin once daily for 5 days (FINA05) or 10 days (FINA10) or 400/500 mg ciprofloxacin for 10 days (CIPRO10); mITT, microbiological intent to treat; cUTI, complicated urinary tract infection; uPN, uncomplicated acute pyelonephritis; cPN, complicated acute pyelonephritis.